NCT05920941

Mass Balance Study of [14C]JAB-21822

Mass Balance Study of [14C]JAB-21822 in China Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Allist Pharmaceuticals, Inc. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Mass Balance Study of \[14C\]JAB-21822 in China Healthy Subjects

Detailed description

A phase I study to quantify the total mass balance in healthy subjects after a single dose of \[14C\]JAB-21822

Conditions

• Mass Balance Study in Healthy Subjects

Interventions

Type	Name	Description
DRUG	[14C]JAB-21822	Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach

Timeline

• Start date: 2023-07-08
• Primary completion: 2023-08-09
• Completion: 2023-08-09
• First posted: 2023-06-27
• Last updated: 2025-04-04

Locations

1 site across 1 country: China